Lumens Bios루멘스바이오스
038060 · KOSDAQ · ₩038060 · 루멘스바이오스
₩854▼ ₩147 (14.69%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩176B | ₩174B | ₩171B | ₩166B | ₩172B |
| Cost of sales | ₩158B | ₩151B | ₩150B | ₩142B | ₩145B |
| Gross profit | ₩18B | ₩23B | ₩21B | ₩25B | ₩28B |
| Operating income | −₩5B | −₩1.6B | ₩2.7B | ₩1.2B | ₩791M |
| Net income | −₩6.7B | ₩8.8B | ₩4B | ₩16B | −₩29B |
| Net income to shareholders | −₩6.7B | ₩8.8B | ₩4B | ₩16B | −₩27B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩156B | ₩168B | ₩146B | ₩138B | ₩183B |
| Current assets | ₩124B | ₩131B | ₩124B | ₩125B | ₩137B |
| Cash and equivalents | ₩60B | ₩53B | ₩57B | ₩42B | ₩38B |
| Total liabilities | ₩50B | ₩57B | ₩49B | ₩44B | ₩109B |
| Current liabilities | ₩40B | ₩47B | ₩47B | ₩42B | ₩107B |
| Borrowings | ₩102M | ₩7B | ₩8.7B | ₩13B | ₩32B |
| Total equity | ₩106B | ₩111B | ₩98B | ₩94B | ₩74B |
| Shareholders' equity | ₩106B | ₩111B | ₩98B | ₩94B | ₩74B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩15B | ₩4.3B | ₩25B | −₩20B | −₩7B |
| Capital spending | ₩2.6B | ₩2.6B | ₩3.5B | ₩2.4B | ₩4.1B |
| Free cash flow | ₩12B | ₩1.8B | ₩21B | −₩22B | −₩11B |
Consolidated where available. Amounts in won.
Also known as: Lumens Bios / 루멘스바이오스 / 038060 / KRX:038060
Source: KRX statistical information